Wire · operational-macro
FDA Clears Roche cobas eplex RP3 Panel for 19 Respiratory Pathogens
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Roche's cobas eplex respiratory pathogen panel 3 (RP3) received FDA 510(k) clearance to detect 19 viral and bacterial respiratory pathogens with results in under two hours, including Bordetella pertussis and updated targets for influenza and SARS-CoV-2. The test offers flexible panel options and supports rapid, automated sample-to-answer workflow aimed at optimising clinical laboratory resources and supporting antimicrobial stewardship.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your clinical diagnostics offering just needs faster results and broader pathogen panels to stay competitive. Rapid FDA clearance of Roche’s test means the bar is rising for quick, multiplexed respiratory pathogen detection to reduce unnecessary treatments and speed patient outcomes.
◆ Coverage
2 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics